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Norovirus (NoV) is recognized as the commonest cause 
of acute gastroenteritis among adults. Susceptibility to dis-
ease has been associated with histo-blood group antigens 
and secretor status; nonsecretors are almost completely 
resistant to disease. We report a foodborne outbreak of 
GI.3 NoV gastroenteritis that affected 33/83 (40%) persons. 
Symptomatic disease was as likely to develop in nonsecre-
tors as in secretors (odds ratio [OR] 1.41, 95% conﬁ  dence 
interval [CI] 0.46–4.36 vs. OR 0.71, 95% CI 0.23–2.18, p 
= 0.57). Moreover, no statistical difference in susceptibility 
was found between persons of different Lewis or ABO phe-
notypes. The capsid gene of the outbreak strain shares high 
amino acid homology with the Kashiwa645 GI.3 strain, pre-
viously shown to recognize nonsecretor saliva, as well as 
synthetic Lewis a. This norovirus outbreak affected persons 
regardless of secretor status or Lewis or ABO phenotypes.
N
orovirus (NoV) is the leading cause of nonbacterial, 
acute gastroenteritis among adults and is responsi-
ble for numerous outbreaks worldwide (1–4). The virus 
is frequently associated with contaminated food, causing 
>50% of all food-related outbreaks (5). Several studies 
(6–11) have associated norovirus susceptibility with the 
presence of an α1,2-linked fucose on histo-blood group 
antigens (HBGAs), which is determined by the FUT2 
gene (12,13). Persons carrying >1 functional FUT2 allele, 
and thus expressing α1,2 fucosyltransferase 2 (FucT-II), 
are termed secretor positive (secretors), and can express 
the A and B blood group antigens as well as H-type 1 and 
Lewis b (Leb) antigens on mucosa and in secretions. Per-
sons lacking FucT-II are termed secretor negative (non-
secretors) and have been shown to be highly protected 
from infections with several NoV genotypes, including 
the common GII.4, as well as the Norwalk virus prototype 
strain (GI.1) (6–11).
Saliva-binding studies have demonstrated that differ-
ent NoV strains exhibit different binding patterns (14–16), 
with the Norwalk virus (GI.1) mainly recognizing saliva 
from secretors with blood groups A and O, while exhibit-
ing low or no binding to saliva to nonsecretors and carriers 
of blood group B, suggesting protection against infection 
among the latter 2 groups. Virus-like particles (VLPs) of 
the common GII.4 strains have been found to mainly bind 
saliva from secretors irrespective of blood group (16), al-
though binding to nonsecretor saliva has been described for 
VLPs of some GII.4 strains (17).
Although NoV infections of secretors are well docu-
mented (18) and a few cases of infected nonsecretors have 
been reported (19,20), no virus has been identiﬁ  ed in au-
thentic outbreaks that is completely secretor or Lewis an-
tigen independent, where homozygous carriers of the non-
sense G428A mutation in FUT2 are at similar or higher risk 
for infection than are secretors. We describe a foodborne 
NoV outbreak in which persons were infected regardless 
of secretor status or Le phenotypes; and no difference was 
observed between nonsecretor (Lea+b−) persons and secre-
tors regarding risk of symptomatic norovirus infection. Our 
data provide new knowledge about susceptibility factors 
and NoV genotypes and suggest that additional studies of 
host genetic receptor factors and NoV are needed.
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Materials and Methods
Outbreak Data and Sample Collection
In October 2007, a NoV gastroenteritis outbreak oc-
curred in Jönköping, Sweden, at a seminar for healthcare 
improvement (October 25–27), attended by 112 healthcare 
workers from different parts of Sweden. The healthcare 
workers were asked to take part in this case–control study, 
and 83 persons, including 4 employees of the restaurant 
that provided food service, decided to participate. Thirty-
three of these 83 persons acquired acute gastroenteritis 
during or shortly after the seminar. Saliva samples were 
collected from all 83 participants in the study and stored 
at –20°C until further use. Stool samples (n = 4) were ob-
tained from the cook, 2 employees, and 1 participant of the 
conference with symptoms of NoV gastroenteritis. Epide-
miologic investigations indicated that the lunch on the ﬁ  rst 
day was contaminated with NoV and was subsequently the 
cause of the outbreak. The cook was ill 4 days before the 
outbreak started, and 3 days later other employees of the 
restaurant became ill, suggesting the restaurant employees 
as the probable source of NoV contamination in the food. 
NoV disease was identiﬁ  ed by at least 1 of the following 
signs or symptoms: vomiting, diarrhea, or nausea combined 
with stomach ache ≈12–60 hours after ingesting the meal. 
Description of symptoms was obtained through a question-
naire sent to all participants in the study. The study was ap-
proved by the local ethics committee (M205-04 T48-08).
DNA Extraction from Saliva
Genomic DNA from 200 μL saliva was extracted by 
using QIAamp DNA Mini Kit (QIAGEN, Hilden, Ger-
many) according to the instructions of the manufacturer 
(Blood and Body Fluid Spin Protocol). Extracted DNA 
was stored in AE buffer (QIAGEN) at –20°C until PCR 
ampliﬁ  cation.
PCR Ampliﬁ  cation of FUT2 and 
Determination of FUT2 428 Genotype 
The FUT2 gene ampliﬁ  cation by PCR was performed 
as previously described (6). Genotyping of the G428A mu-
tation in the FUT2 gene was performed as previously de-
scribed (6,7,21). These methods can distinguish between 
carriers of the homozygous wild-type, heterozygous, and 
homozygous mutated genotype.
Detection of Histo-Blood Group Antigens in Saliva
The ABO histo-blood group phenotype of secretor-
positive persons and the Lewis phenotype of all 83 persons 
were determined by a saliva-based ELISA, essentially as 
described by Bucardo et al. (6) and Rydell et al. (22). Pro-
tein concentration was determined in boiled (5 min) and 
centrifuged (5 min, 10,000 rpm) saliva by means of a Brad-
ford assay. ELISA plates (NUNC 96F Maxisorp; Thermo 
Fisher Scientiﬁ  c, Roskilde, Denmark) were coated with 
saliva, diluted to a ﬁ  nal protein concentration of 1 μg/mL 
in coating buffer (0.1 M carbonate–bicarbonate buffer, pH 
9.6); plates were incubated for 2 h at 37°C followed by 
4°C overnight. The following day, the plates were washed 
4 times with washing buffer (0.9% NaCl, 0.05% Tween 
20 [Sigma-Aldrich, St. Louis, MO, USA]), and then incu-
bated for 1.5 h at 37°C with antibodies α-A (ABO1 clone 
9113D10), α-B (ABO2 clone 9621A8) (Diagast, Loos Ce-
dex, France), α-Lea (Seraclone, LE1 clone 78FR 2.3), and 
α-Leb (Seraclone LE2 clones LM129-181 and 96 FR2.10) 
(Biotest AG, Dreieich, Germany). Antibodies were diluted 
1:5000 in phosphate-buffered saline with 10% fetal bovine 
serum (Invitrogen AB, Lidingö, Sweden) and 0.05% Tween 
20 (Sigma-Aldrich). After 4 washes, horseradish perox-
idase–conjugated goat anti-mouse IgG (heavy plus light 
chain) (Bio-Rad Laboratories, Hercules, CA, USA), diluted 
1:7,500, was added, and plates were incubated for another 
1.5 h at 37°C and subjected to 4 ﬁ  nal washes. The reac-
tion was developed using 3′,3′,5′,5-tetramethylbenzidine 
(DakoCytomation, Carpinteria, CA, USA), and stopped by 
addition of 2M H2SO4. The plate was read at 450 nm in a 
spectrophotometer. The cutoff value was twice the mean 
level of 6 known negative samples. The α-Leb antibody 
cross-reacted weakly with Lea; this signal was subtracted 
from the Leb values read in Lea-positive persons.
Virus RNA Extraction and Reverse Transcription
RNA extraction from the 4 collected stool specimens 
was performed by using the EZ1 robot (QIAGEN) ac-
cording to the manufacturer’s instructions and stored at 
–80°C until used for reverse transcription. Reverse tran-
scription was performed as previously described (6,23), 
by using random hexamer primers (GE Healthcare, Upp-
sala, Sweden) and Illustra Ready-To-Go RT-PCR beads 
(GE Healthcare).
Norovirus Detection with Real-Time PCR  
NoV detection and quantiﬁ  cation were performed with 
a real-time PCR speciﬁ  c for the open reading frame (ORF) 
1–ORF2 junction, as described by Nordgren et al. (24). 
This real-time PCR assay can semiquantify and distinguish 
between NoVs GI and GII (24). PCR ampliﬁ  cation of the 
N-terminal and shell (N/S) region was performed on a PTC-
100TM thermal cycler (MJ Research Inc., South San Fran-
cisco, CA, USA) in a 50-μL mixture composed of 1.33 U of 
Expand High Fidelity polymerase (Boehringer Mannheim 
GmbH, Mannheim, Germany), 5 μL of the supplied buf-
fer (including 1.5 mmol/L MgCl2;  Boehringer Mannheim 
GmbH), 100 μM GeneAmp dNTP mixture with dTTP (Ap-
plied Biosystems, Branchburg, NJ, USA), 200 nM forward 
primer NVG1f1b (5′-CGY TGG ATG CGN TTC CAT 
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GA-3′) (24),  200 nM reverse primer G1SKR (5′-CCA ACC 
CAR CCA TTR TAC A-3′) (25), and 5 μL template DNA.
Nucleotide Sequencing of the Norovirus N/S 
Region and Virus Genotyping
Nucleotide sequencing of the N/S region was per-
formed by Macrogen Inc. (Seoul, South Korea). The 
sequencing reaction was based on BigDye chemistry; 
NVG1f1b forward primer (24) and G1SKR reverse primer 
(25) were used as sequencing primers. The amplicons were 
sequenced twice in each direction. Sequence alignment of 
the Jönköping (JKPG) strain and reference NoV genotypes 
was performed by using the ClustalW algorithm, version 
1.8 (www.ebi.ac.uk/clustalw), with default parameters, on 
the European Bioinformatics Institute server. We performed 
phylogenetic analysis using the MEGA 4.0 software pack-
age (www.megasoftware.net), and the phylogenetic tree 
was constructed using the neighbor-joining and Kimura 
2-parameter methods. Signiﬁ  cance of the taxonomic rela-
tionships was obtained by bootstrap resampling analysis 
(1,000 replications). Assignment of genotypes used refer-
ence strains described by Zheng et al. (26).
PCR Ampliﬁ  cation of the Norovirus Capsid Gene
To amplify the gene encoding the NoV capsid, we set 
up a PCR mixture containing 2.5 μL 10× native Pyrococ-
cus furiosus (pfu) polymerase buffer (Invitrogen AB, Lid-
ingö, Sweden), 200 μM GeneAmp dNTP mix with dTTP 
(Applied Biosystems), 200 nM forward primer CapGI3fw 
(5′-GAT CTC CTG CCC GAT TAT GTA AAT GAT GAT 
G-3′, this study), targeting the end of ORF1 and begin-
ning of ORF2, 200 nM reverse primer CapGI3rv (5′-CAT 
TAT GAT CTC CTA ATT CCA AGC CTA CGA GC-3′, 
this study), speciﬁ  c for the end of ORF2 and beginning of 
ORF3, 5 μL cDNA, 2.5 U native pfu DNA polymerase 
(Stratagene, La Jolla, CA, USA), and 36 μL RNAse-free 
water. After initial denaturation at 94°C for 5 min, PCR 
ampliﬁ  cation was performed with 40 cycles of 94ºC for 1 
min, 58ºC for 1 min, and 72ºC for 2 min, and thereafter a 
ﬁ  nal elongation at 72ºC for 10 min. The PCR products were 
visualized by electrophoresis on a 2% agarose gel, using 
staining with ethidium bromide and UV transillumination.
Cloning of the Norovirus Capsid Gene 
and Nucleotide Sequencing
The capsid fragment was cloned into a pPCR-Script 
Amp SK(+) vector and transformed into XL10-Gold Kan 
ultracompetent cells, using the Stratagene PCR-Script Amp 
Cloning Kit (Stratagene) according to the manufacturer’s 
instructions. After overnight incubation of 2 separate colo-
nies from each transformation reaction, plasmid DNA was 
extracted and puriﬁ   ed, using the Plasmid Miniprep Kit 
(QIAGEN) according to the manufacturer’s instructions. 
Nucleotide sequencing was performed on 2 separate plas-
mid extractions from each sample (n = 2) by Macrogen Inc., 
by using the BigDye chemistry with M13 forward and re-
verse primers. The nucleotide sequences for the N/S region 
or the complete capsid gene of the JKPG isolates are avail-
able under GenBank accession nos. FJ711163, FJ711164, 
and FJ711165.
Statistical Analysis
Categorical data were analyzed using the Fisher ex-
act test with 2-tailed signiﬁ  cance. Unadjusted odds ratios 
(ORs) and 95% conﬁ  dence intervals (CIs) were calculated 
using SPSS 14.0 for Mac (SPSS Inc., Chicago, IL, USA).
Results
Outbreak Description
A total of 83 persons responded to the questionnaire 
and participated in the study. Among them, 33 (40%) were 
symptomatic, and 50 (60%) reported no symptoms. The 
latter group may include exposed asymptomatic as well as 
nonexposed persons. The onset of symptoms varied from 1 
through 3 days (mean 36 h) after ingestion of the contami-
nated meal (Figure 1); mean duration of symptoms was 
35 h. The most common symptoms were vomiting (23/32, 
72%), diarrhea (20/32, 63%), joint pain (18/32, 56%), and 
headache (14/32, 44%). Most symptomatic persons (n = 
30) had diarrhea, vomiting, or both, whereas the remaining 
3 persons had nausea and stomach ache.
Distribution of ABO and Lewis Phenotypes 
and Secretor Status 
To investigate whether persons associated with the 
outbreak had a skewed HBGA proﬁ   le, we determined 
the ABO, Lewis, and secretor status distributions among 
symptomatic and asymptomatic/nonexposed persons and 
compared them with results from earlier investigations of 
the population in Sweden (Table 1). The ABO, Lewis, and 
secretor status distributions were in the normal ranges com-
pared with those investigations (Table 1), with the excep-
tion of the AB and Lewis negative phenotypes. Further-
more, we observed that all HBGAs investigated, except AB 
(n = 1), were found among asymptomatic/nonexposed and 
symptomatic persons. Sixty-one persons were secretor and 
Lewis positive; of these, 52 (85%) were positive for Lea 
and Leb in saliva. The 4 persons from whom NoV was iso-
lated were all secretors, having ALea−b+, ALea−b+, OLea−b−, 
and OLea−b+ HBGA proﬁ  les, respectively.
Difference in Susceptibility to Symptomatic
Infection between Secretors and Nonsecretors
Previous studies have shown a strong correlation be-
tween symptomatic NoV infections and the secretor-positive 
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phenotype (7–10). To investigate whether secretor and Lew-
is status were associated with susceptibility in this study, se-
cretor and Lewis status were determined by genotyping and 
phenotyping of all persons. We observed that 7/15 (47%) 
nonsecretors were symptomatically infected, compared with 
26/68 (38%) secretors (Table 1). Although the calculated 
OR for nonsecretors was ≈2× that of secretors (OR 1.41 vs. 
0.71), the differences were not signiﬁ  cant (Table 2). Thus, in 
the group studied, nonsecretors were as likely as secretors to 
be symptomatically infected by norovirus. The same pattern 
was observed for the Lewis phenotypes; no statistical differ-
ence was found between persons with Lea+b−, Lea−b+, or Lea−b− 
regarding risk for symptomatic infection (Table 2). None of 
the Lewis-negative nonsecretors (n = 3) were symptomati-
cally infected. The FUT2 G428A genotyping did not show 
any signiﬁ  cant differences between heterozygous secretors 
and homozygous secretors (OR 1.20, 95% CI 0.49–2.95 vs 
OR 0.67, 95% CI 0.27–1.65; Table 2).
Association between ABO Blood Types 
and Symptomatic Infection
Previous studies have shown that ABO blood types are 
associated with susceptibility to symptomatic NoV infec-
tions, with persons having blood type B at lower risk of in-
fection when challenged with Norwalk virus (GI.1) (8,28). 
In this outbreak, we found that symptoms developed in 2/12 
(17%) of persons with blood group B (Table 1). Although 
persons with blood group B were infected to a lesser ex-
tent than persons with other blood groups, this reduction 
was not signiﬁ  cant (OR 0.27, 95% CI 0.05–1.33; Table 2). 
Furthermore, no signiﬁ  cant differences were found when 
comparing symptomatic and nonsymptomatic persons with 
blood types A and O (OR 1.56, 95% CI 0.58–4.16, and OR 
1.39, 95% CI 0.50–3.89, respectively) (Table 2). Thus, no 
blood type provided complete protection or was associated 
with a higher or lower risk for disease.
Association between Blood Type, Secretor 
Status, and Clinical Symptoms
A recent study suggested that blood type can have an 
inﬂ  uence on clinical symptoms after NoV infection (29). 
To investigate whether this would apply in this outbreak, 
blood types, secretor status, and clinical symptoms were 
compared. We did not ﬁ  nd any correlation between blood 
type and secretor status with clinical symptoms (Table 3).
Similarity of JKPG and Kashiwa645 Strains in 
the P2 Domain and Putative Receptor Binding Sites
NoV GI was detected by real-time PCR in all collected 
stool specimens (n = 4); three of these isolates (881–883) 
were subsequently genotyped by nucleotide sequencing of 
the N/S region. The fourth sample could not be genotyped 
because of low virus concentration in the stool sample. 
Phylogenetic analysis clustered the 3 isolates with NoV 
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Figure 1. Time to onset of symptoms after patient exposure to 
norovirus-contaminated food (n = 30), Sweden. Zero indicates the 
time point for serving and ingesting the contaminated food.
Table 1. Distribution of histo-blood group antigens phenotypes and secretor status among 83 participants in a case–control study of a 
norovirus gastroenteritis outbreak in Sweden, 2007* 
Antigen and secretor 
status
No. (%) symptomatic 
persons, n = 33 
No. (%) asymptomatic/ 
nonexposed persons, n = 50†  
Total no. (%) persons, 
n = 83 
Normal distribution, 
% (95% CI)†‡ 
Blood type (n = 68) 
  A  14 (44)  18 (56)  32 (47)  47 (37–56) 
  B  2 (17)  10 (83)  12 (18)  15 (8–22) 
  O  10 (43)  13 (57)  23 (34)  33 (23–40) 
  AB  0 1 (100)  1 (1)  7 (2–12) 
Lewis (n = 83) 
 Le
a+b– 7 (58)  5 (42)  12 (14)  18 (11–26) 
 Le
a–b+ 23 (38)  38 (62)  61 (73)  76 (68–84) 
 Le
a–b– 3 (30)  7 (70)  10 (12)  6 (1–10) 
Secretor status (n = 83) 
  Secretor§   26 (38)  42 (62)  68 (82)  80 (72–88) 
  Nonsecretor  7 (47)  8 (53)  15 (18)  20 (12–28) 
*ABO blood group could only be determined for the 68 secretor-positive persons (26 symptomatic and 42 asymptomatic). CI, confidence interval.
†p>0.15. 
‡See Larsson et al. (27). 
§Homozygous and heterozygous. Norovirus Gastroenteritis Outbreak
GI.3 strains (data not shown). The entire capsid gene was 
subsequently sequenced from 2 isolates and compared with 
reference strains (Figure 2). The closest amino acid simi-
larity (98.0%) of the complete capsid gene was found with 
strain PD196-DEU (GI.3), isolated in Germany 2000, and 
with the Kashiwa645 (GI.3) strain (97.8%), used in an ear-
lier VLP binding study (14).
We then investigated the amino acid composition of the 
capsid P2 domain of the outbreak strain and compared it with 
the Kashiwa645 and Norwalk strains. Although the JKPG 
strain differed by 4 aa at positions 344, 367, 377, and 397 
(97.1% homology) compared with Kashiwa645, it shared 
only ≈50% aa positions with the GI.1 Norwalk strain.
Discussion
Previous studies have shown a strong (6–11) but not 
absolute (19,20) association between nonsecretors and 
protection from symptomatic NoV disease. In contrast to 
these observations, we report a foodborne NoV outbreak 
affecting persons regardless of secretor, Lewis, or ABO 
phenotype.
Because the host genetic observation of this outbreak 
was unexpected, attempts were made to compare the 
HBGA frequencies of the participating persons with those 
of the population in Sweden. The ABO, secretor, and Lewis 
phenotype frequencies in this study agreed with results 
from earlier investigations from the population in Sweden 
(21,27) (Table 1), with the exception of the AB and Lewis 
negative phenotypes, probably due to their low prevalence 
in combination with the small sampling set. Seven (8%) se-
cretor and 3 (4%) nonsecretor persons were Lewis negative 
and hence lacked Lewis antigen in saliva. Genotyping of 
the FUT2 G428A nonsense mutation conﬁ  rmed secretor-
negative genotype of all Lea+b− persons and the secretor-
positive genotype of Lea−b+ persons.
Comparison of secretor and Lewis phenotypes regard-
ing susceptibility to symptomatic NoV infection showed 
that nonsecretors were as susceptible to symptomatic dis-
ease as secretors. Consistent with the lack of secretor asso-
ciation, no signiﬁ  cant difference in susceptibility was noted 
between Lea+b− and Lea−b+ persons (OR 2.42, 95% CI 0.70–
8.42 vs. OR 0.73, 95% CI 0.27–1.95). None of the nonse-
cretors who were also Lewis negative (n = 3), hence lacking 
the Lea antigen and ABO in saliva, were symptomatically 
infected. These ﬁ  ndings indicate but do not prove that the 
Lea antigen is a putative receptor for this norovirus strain. 
The disease pattern of this outbreak is consistent with the 
ﬁ  ndings by Shirato et al. (14), who observed strong binding 
to synthetic Lea and saliva from secretors and nonsecretors 
with VLPs from the GI.3 Kashiwa645 strain, which shares 
high homology with the JKPG strain in the P2 domain. A 
mechanistic virus–saliva binding study with the authentic 
virus would have been desirable, but limited amounts of 
virus restricted our attempts to investigate if the outbreak 
virus binds to saliva both from secretors and nonsecretors.
No ABO phenotype provided protection or was asso-
ciated with a higher risk of disease, although persons with 
blood type B exhibited a low (17%) frequency of symptom-
atic infection (Tables 1, 2). Blood type B has previously 
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Table 2. Influence of secretor status, FUT2 polymorphism, and 
histo-blood group antigens on risk for norovirus GI.3 symptomatic 
infection, Sweden* 
Secretor status  OR (95% CI)  p value 
  Secretor, n = 68  0.71 (0.23–2.18)  0.57
  Nonsecretor, n = 15  1.41 (0.46-4.36)  0.57
FUT2 428 polymorphism 
  G/G (secretor), n = 35   0.67 (0.27–1.65)  0.50
  G/A (secretor), n = 33  1.20 (0.49–2.95)  0.82
  A/A (nonsecretor), n = 15  1.41 (0.46–4.36)  0.57
Histo-blood group antigens 
  Blood type,† n = 68 
    A, n = 32  1.56 (0.58–4.16)  0.46
    B, n = 12    0.27 (0.05–1.33)  0.11
    O, n = 23  1.39 (0.50–3.89)  0.60
    AB, n = 1  Not applicable‡  1.0
  Lewis, n = 83 
  L e
a+b–, n = 12  2.42 (0.70–8.42)  0.21
  L e
a-b+, n = 61  0.73 (0.27–1.95)  0.61
  L e
a–b–, n = 10  0.61 (0.15–2.57)  0.73
*FUT, fucosyltransferase; OR, odds ratio; CI, confidence interval.
†Compared between secretors. ABO blood group could only be 
determined for the 68 secretor-positive persons. 
‡No carrier of blood type AB was symptomatically infected with norovirus. 
Table 3. Relationship between clinical symptoms of norovirus infection and secretor status and blood type distribution among 83
participants in a case–control study of a norovirus gastroenteritis outbreak in Sweden, 2007* 
No. (%) persons reporting symptom 
Data Diarrhea Vomiting Joint pain  Headache
Blood type 
  A, n = 14  9 (64)  12 (86)  9 (64)  7 (50) 
  B, n = 2†  1 (50)  0 (0)  0 (0)  0(0)
  O, n = 9‡  6 (67)  6 (67)  4 (44)  5 (56) 
Secretor, n = 25‡  16 (64)  18 (72)  13 (52)  12 (48) 
Nonsecretor, n = 7  4 (57)  5 (71)  5 (71)  2 (29) 
Total 20 (63)  23 (72)  18 (56)  14 (44) 
*HBGA, histo-blood group antigen. 
†One person with HBGA type B experienced only nausea and stomachache.
‡One secretor-positive person with HBGA type O did not provide a description of symptoms. RESEARCH
been associated with protection from disease when chal-
lenged with the Norwalk virus (28) and was also supported 
by in vitro binding studies with VLPs (16). Shirato et al. 
(14) found that the Kashiwa645 (GI.3) VLP bound weaker 
to saliva from blood type B-positive persons compared 
with types A and O, which agrees with the disease pattern 
observed in this outbreak. It is possible that the α-gal in the 
blood type B structure partly covers an epitope needed for 
binding and hence decreases the ability of the JKPG strain 
to infect carriers of blood type B.
One limitation of our study is that some of the asymp-
tomatic persons may not have been exposed to the virus. 
This possibility could result in sampling artifacts because 
symptoms could have developed in the unexposed (and thus 
seemingly protected) persons if they had been exposed. 
However, this possibility is unlikely to inﬂ  uence the main 
ﬁ  ndings of this study, namely the secretor- and HBGA-in-
dependent infection pattern, because symptomatic persons 
were found in all HBGA groups.
An advantage with genotyping compared with pheno-
typing is that the roles of heterozygosity and homozygosity 
in disease susceptibility can be investigated. In this study, 
we did not observe any signiﬁ  cant differences between 
heterozygous and homozygous secretors (OR 1.20, 95% 
CI 0.49–2.95 vs. OR 0.67, 95% CI 0.27–1.65) (Table 2), 
which is in agreement with earlier observations (7,9).
By comparing our strain with a reference strain of the 
same cluster (Kashiwa645) used in earlier binding studies 
(14), we aimed to elucidate structural similarities or differ-
ences that could explain the unique disease proﬁ  le of the 
outbreak. The JKPG strain investigated in this outbreak 
shares high amino acid homology with the GI.3 Kashi-
wa645 strain (Figure 2). Shirato et al. (14) found that the 
Kashiwa645 strain bound to the same extent to secretor and 
nonsecretor saliva. However, another consideration is that 
Asian nonsecretors in the study (14) were identiﬁ  ed as car-
riers of a missense mutation at nt 385 (A→T) and thus are 
incomplete nonsecretors, producing small amounts of ABO 
and Leb HBGA in secretions. The similarities between the 
binding proﬁ  le of the Kashiwa645 strain and the disease 
proﬁ  le of the JKPG strain indicate that saliva binding may 
be used to assess susceptibility patterns for individual NoV 
strains.
In conclusion, we report a foodborne NoV outbreak 
infecting persons irrespective of Lewis and secretor status, 
with Lea+b− persons homozygous for the FUT2 G428A non-
sense allele being symptomatically infected at similar rates 
compared with secretors. Our observed disease pattern is in 
concordance with saliva binding speciﬁ  cities of VLP based 
on the Kashiwa645 strain, sharing high homology in the 
P2 domain with the JKPG strain. Increased knowledge of 
susceptibility factors for norovirus disease will be helpful 
in the development of preventive or therapeutic measures 
for infection.
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